Dear Editor,
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global Status Report on Noncommunicable Diseases.World Health Organization, Geneva2010 (Available from) (Ultimo accesso 20 gennaio 2014)
- Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.J Cardiovasc Med. 2018; 19: 75-77
- [Improving compliance in internal medicine: the motivational discussion].Ann Ital Med Int. 2004; 19: 155-162
- Interventions to enhance patient adherence to medication prescriptions.JAMA. 2002; 288: 2868-2879
- Adherence to medication.N Engl J Med. 2005; 353: 487-497
- Persistence of use of lipid-lowering medications: a cross-national study.JAMA. 1998; 279: 1458-1462
Classificazione del medicinale per uso umano «Repatha», ai sensi dell'art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n.172/2017) (17A01047). 2017], [AIFA (Agenzia Italiana del Farmaco). Gazzetta Ufficiale n.24 del 06 marzo 2017.
- The dyslipidaemia market.Nat Rev Drug Discov. 2014; 13: 807-808
- Patient adherence to treatment: three decades of research. A comprehensive review.J Clin Pharm Ther. 2001; 26: 331-342
- Stein EA; DESCARTES investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.N Engl J Med. 2014; 370: 1809-1819
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.Am Heart J. 2015; 169 (e13): 906-915
- Cost-effectiveness study on the use of pcsk9 inhibitors in Tuscany - CERTI study.Giornale Italiano Dell'Arterioscler. 2020; 11: 30-47
Article info
Publication history
Published online: March 07, 2023
Accepted:
March 3,
2023
Received:
November 22,
2022
Publication stage
In Press Corrected ProofFootnotes
☆No part of the submitted work has been published or is under consideration for publication elsewhere.
Identification
Copyright
© 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
